Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Glycoconj J. 2014 Oct;31(0):509–521. doi: 10.1007/s10719-014-9548-4

Figure 3. Enzyme activity in patient tumor versus normal control tissue.

Figure 3

Enzyme activity assays were performed identical to Figure 2 using breast, colon or prostate tumor or normal tissue as enzyme source. Enzyme activities measured include: A. β1,3GalT using GalNAcα-PABA acceptor; B. β1,4GalTusing Galβ1,3(GlcNAcβ1,6)GalNAcα-O-Bn; C. α1,3-FT[Galβ1,4GlcNAcβ] using Galβ1,4GlcNAcβ1,3Galβ1,4GlcNAcβ-O-Bn; D.α1,4-FT[Galβ1,3GlcNAc] activity using Galβ1,3GlcNAcβ1,3lacβ-Φ-NO2; E. ST3/6[Galβ1,3GalNAc] using Galβ1,3GalNAcα-sp-biotin; F. ST3/6[Galβ1,4GlcNAc] using Galβ1,4GlcNAcβ1,3Galβ1,4GlcNAcβ-O-Bn; and G. ST3[Galβ1,3GalNAc] using Galβ1,3(GlcNAcβ1,6)GalNAcα-O-Bn. Data are represented as box plots where the top, middle and bottom of the box represent the upper (Q1), median (Q2) and lower (Q3) quartiles of the observations. The ends of the whiskers represent the maximum or minimum data points within 1.5 times the height of the box, while points indicated by are outliers. Pictorial representation of products formed on top of each panel follow Consortium for Functional Glycomics (CFG) nomenclature. * P<0.05 and **P<0.005 compared to normal tissue.

HHS Vulnerability Disclosure